CDKN2B-AS1 and coronary artery disorder: However, CHD clinical risk algorithms such as Framingham or QRISK include circulating lipoproteins only.8,9 Importantly, bioactive lipids that regulate vascular inflammation/proliferation in line with the function of ANRIL and thus may be directly relevant to Chr9p21-mediated CHD are not included in these measures.